In general, the first line of treatment for<unk>  is chemotherapy. A few of these regimens are: the GMALL-B-ALL/NHL2002 protocol, the modified Magrath regimen (R-CODOX-M/IVAC). COPADM, hyper-CVAD, and the Cancer and Leukemia Group B (CALGB) 8811 regimen; these can be associated with rituximab. In older patients, treatment may be dose-adjusted EPOCH with rituximab. The effects of the chemotherapy, as with all cancers, depend on the time of diagnosis. With faster-growing cancers, such as<unk> , the cancer actually responds faster than with slower-growing cancers. This rapid response to chemotherapy can be hazardous to the patient, as a phenomenon called "tumor lysis syndrome" could occur. Close monitoring of the patient and adequate hydration is essential during the process. Since<unk>  has high propensity to spread to the central nervous system (lymphomatous meningitis), intrathecal chemotherapy with methotrexate and/or ARA-C and/or prednisolone is given along with systemic chemotherapy. Chemotherapy * cyclophosphamide * doxorubicin * vincristine * methotrexate * cytarabine * ifosfamide * etoposide * rituximab Other treatments for<unk>  include immunotherapy, bone marrow transplants, stem cell transplant, surgery to remove the tumor, and radiotherapy.
Burkitt lymphoma
Hodgkin lymphoma
AIDS-related lymphoma
Thymic carcinoma
B-cell lymphoma
Thymoma with immunodeficiency
Diffuse large B-cell lymphoma
Mantle cell lymphoma